A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy

European Urology

Volumn 65, Issue 5, 2014, Pages 897-904

  Wirth, Manfred ^a   Heidenreich, Axel ^b   Gschwend, Jürgen E ^c   Gil, Thierry ^d   Zastrow, Stefan ^a   Laniado, Michael ^a   Gerloff, Joachim ^e   Zühlsdorf, Michael ^e   Mordenti, Giacomo ^e   Uhl, Wolfgang ^e   Lannert, Heinrich ^e  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d JULES BORDET INSTITUTE   (Belgium)

^e MERCK KGAA   (Germany)

Author keywords

Castrate resistant prostate cancer (CRPC); EMD 525797; v Integrin overexpression

Indexed keywords

ANTINEOPLASTIC AGENT; CD51 ANTIGEN; EMD 525797; GAMMA GLUTAMYLTRANSFERASE; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLURRED VISION; BONE METASTASIS; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; ELEVATED BLOOD PRESSURE; ERYTHEMA; FATIGUE; HISTOPATHOLOGY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MUCOSA INFLAMMATION; MULTICENTER STUDY; MUSCLE WEAKNESS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RHINITIS; SENSORY NEUROPATHY; SEPTICEMIA; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TONGUE SWELLING; TREATMENT DURATION; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; URETER OBSTRUCTION; XEROSTOMIA;

CASTRATE-RESISTANT PROSTATE CANCER (CRPC); EMD 525797; ΑV-INTEGRIN OVEREXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ERUPTIONS; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INTEGRIN ALPHAV; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SEPSIS;

EID: 84896402680     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.05.051     Document Type: Article

References (30)

1. M. Bishr, J.B. Lattouf, P.O. Gannon, and F. Saad Updates on therapeutic targets and agents in castration-resistant prostate cancer Minerva Urol Nefrol 63 2011 131 143
2. K. Lassi, and N.A. Dawson Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives Future Oncol 7 2011 551 558
3. M. Merino, A. Pinto, R. González, and E. Espinosa Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer Eur J Cancer 47 2012 1846 1851
4. R.K. Assoian, and M.A. Schwartz Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression Curr Opin Genet Dev 11 2001 48 53
5. C.R. Cooper, and K.J. Pienta Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview Prostate Cancer Prostatic Dis 3 2000 6 12
6. S.P. Holly, M.K. Larson, and L.V. Parise Multiple roles of integrins in cell motility Exp Cell Res 261 2000 69 74
7. J.D. Hood, and D.A. Cheresh Role of integrins in cell invasion and migration Nat Rev Cancer 2 2002 91 100
8. E. Ruoslahti, and J.C. Reed Anchorage dependence, integrins, and apoptosis Cell 77 1994 477 478
9. J.K. Slack-Davis, and J.T. Parsons Emerging views of integrin signaling: implications for prostate cancer J Cell Biochem 91 2004 41 46
10. K. Chen, and X. Chen Integrin targeted delivery of chemotherapeutics Theranostics 1 2011 189 200
11. S.L. Goodman, and M. Picard Integrins as therapeutic targets Trends Pharmacol Sci 33 2012 405 412
12. M. Fornaro, T. Manes, and L.R. Languino Integrins and prostate cancer metastases Cancer Metastasis Rev 20 2001 321 331
13. S.M. Albelda Role of integrins and other cell adhesion molecules in tumor progression and metastasis Lab Invest 68 1993 4 17
14. C.R. Cooper, C.H. Chay, and K.J. Pienta The role of alpha(v)beta(3) in prostate cancer progression Neoplasia 4 2002 191 194
15. M. Schmelz, A.E. Cress, and K.M. Scott et al. Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites Neoplasia 4 2002 243 254
16. R.B. Shah, R. Mehra, and A.M. Chinnaiyan et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program Cancer Res 64 2004 9209 9216
17. J.A. Nemeth, M.L. Cher, Z. Zhou, C. Mullins, S. Bhagat, and M. Trikha Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases Clin Exp Metastasis 20 2003 413 420
18. L.T. Duong, P. Lakkakorpi, I. Nakamura, and G.A. Rodan Integrins and signaling in osteoclast function Matrix Biol 19 2000 97 105
19. D.E. Hughes, D.M. Salter, S. Dedhar, and R. Simpson Integrin expression in human bone J Bone Miner Res 8 1993 527 533
20. I. Nakamura, M.F. Pilkington, and P.T. Lakkakorpi et al. Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone J Cell Sci 112 1999 3985 3993
21. J.A. Nemeth, M.T. Nakada, and M. Trikha et al. Alpha-v integrins as therapeutic targets in oncology Cancer Invest 25 2007 632 646
22. C.F. Lai, and S.L. Cheng Alphavbeta integrins play an essential role in BMP-2 induction of osteoblast differentiation J Bone Miner Res 20 2005 330 340
23. N.P. McCabe, S. De, A. Vasanji, J. Brainard, and T.V. Byzova Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling Oncogene 26 2007 6238 6243
24. G. van der Horst, C. van den Hoogen, and J.T. Buijs et al. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer Neoplasia 13 2011 516 525
25. F. Mitjans, D. Sander, and J. Adán et al. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice J Cell Sci 108 1995 2825 2838
26. M. Zühlsdorf, A. Kovar, W. Uhl, and U. Forssmann Safety, tolerability and pharmacokinetics of the novel αv-integrin antibody DI17E6 in healthy subjects after ascending single intravenous doses [abstract 1296] Cancer Res 2011 71
27. Meibohm B, Brockhaus B, Zuehlsdorf M, Kovar A. PK/PD model-based drug development of EMD 525797 (DI17E6), a novel anti-αv integrin monoclonal antibody. Abstract presented at: 2013 American Society for Clinical Pharmacology and Therapeutics annual meeting; March 5-9, 2013; Indianapolis, IN, USA.
28. S.L. Du Pen, A.R. Du Pen, and N. Polissar et al. Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial J Clin Oncol 17 1999 361 370
29. D.R. Mould, and B. Green Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development BioDrugs 24 2010 23 39
30. J. Michels, T. Montemurro, N. Murray, C. Kollmannsberger, and K. Nguyen Chi First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer Cancer 106 2006 1041 1046